Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2754)	4/9/2010 6:31:36 PM
From: Jibacoa	Respond to of 3722

RPC was up 184.5% at its intraday H and closed up 108.51% on volume of 44,659,989 about 51.6x its ADV. <G> RPC is still doing well AHs (Up 4.02% from the close at present.)<g> The stock has been up for the 4th day on a roll with sequentially increasing volume.<g> bigcharts.marketwatch.com On Wednesday it announced that it has entered into an agreement with Jaiva Technologies which wil collaborate in India to conduct clinical trials for RPC's Combination Immunogene Therapy (CIT) technology and will support RPC in securing Indian government approval for the use of CIT as a cancer therapy and vaccine throughout the country. On Thursday it commented about the monoclonal antibody test, which it began working on twenty years ago and the FDA and many other international agencies have already approved,how it may change the way people screen for early cancer detection. Under the agreement with Jaiva, JTGD has the exclusive rights to distribute RPC's Onko-Sure in vitro diagnostic cancer test in India and is responsible for product sales, marketing, and governmental regulatory in the territory. Today it announced that it has extended its partnership with GenWay Biotech Inc., and has signed a 5-year marketing, sales and distribution agreement for the commercialization of RPC's Onko-Sure in vitro diagnostic cancer (IVD) test in Russia and the former Soviet Republics. Today StockPreacher also announced an investment report featuring RPC.The full report is available at: stockpreacher.com RPC was able to trade today above the Jan2009 H of $1.62 and the Oct208 H of $1.90 The next resistance is today's intraday H of $2.02 which took place at 2:25PM EST. It was really nice to trade RPC this week.<G> bigcharts.marketwatch.com I still have fond memories of RPC's April-Oct run from $5 to $25 in 2001 and the shorter run (Jan-March) from $8 to $21.95 in 2002 (I didn't traded it in 2003) There is no ACTAY, but I will keep my 12M target at $5 <g> bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (2754)	6/2/2010 11:40:07 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

GENT reached my target of $5 in April and traded at $5.86 on April 19 <g> Today the stock is down and is presently testing support at yesterday's L of $4.41. It seems it may come down to the $4.20 level as it needs to regroup before it is able to go through the $5 resistance again. bigcharts.marketwatch.com Last week it reported its 1stQ results, which showed a good increase in revenues and it reported earnings on the black at $0.08 vs. loss of $0.27 in 2009 This is the 3rd time that GENT has reported better revenues, which have also shown sequential improvement. GENT was cash flow positive at the end of the 1stQ and said that it expects to remain cash flows positive/neutral throughout 2010 <g> I took profits in April, but plan on buying back some shares if GENT can close above $5 They still need to complete certain preclinical and clinical studies before they are able to file a new NDA for Defibrotide. <g> The ACTAY is $5 But with some good news and a close above $5 I will place a target at $10. As always, it is better to keep a trailing stop loss.<g> bigcharts.marketwatch.com Bernard